127 related articles for article (PubMed ID: 30021999)
1. Efficient Lead Finding, Activity Enhancement and Preliminary Selectivity Control of Nuclear Receptor Ligands Bearing a Phenanthridinone Skeleton.
Nishiyama Y; Fujii S; Makishima M; Hashimoto Y; Ishikawa M
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30021999
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (RORγ)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand.
Nishiyama Y; Nakamura M; Misawa T; Nakagomi M; Makishima M; Ishikawa M; Hashimoto Y
Bioorg Med Chem; 2014 May; 22(9):2799-808. PubMed ID: 24702856
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel ROR inverse agonists with a dibenzosilole scaffold as a hydrophobic core structure.
Toyama H; Nakamura M; Hashimoto Y; Fujii S
Bioorg Med Chem; 2015 Jul; 23(13):2982-8. PubMed ID: 26014484
[TBL] [Abstract][Full Text] [Related]
4. Novel non-steroidal/non-anilide type androgen antagonists: discovery of 4-substituted pyrrole-2-carboxamides as a new scaffold for androgen receptor ligands.
Wakabayashi K; Miyachi H; Hashimoto Y; Tanatani A
Bioorg Med Chem; 2005 Apr; 13(8):2837-46. PubMed ID: 15781394
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.
Motoshima K; Ishikawa M; Hashimoto Y; Sugita K
Bioorg Med Chem; 2011 May; 19(10):3156-72. PubMed ID: 21514830
[TBL] [Abstract][Full Text] [Related]
6. Compound profiling using a panel of steroid hormone receptor cell-based assays.
Wilkinson JM; Hayes S; Thompson D; Whitney P; Bi K
J Biomol Screen; 2008 Sep; 13(8):755-65. PubMed ID: 18753690
[TBL] [Abstract][Full Text] [Related]
7. Non-steroidal steroid receptor modulators.
Buijsman RC; Hermkens PH; van Rijn RD; Stock HT; Teerhuis NM
Curr Med Chem; 2005; 12(9):1017-75. PubMed ID: 15892636
[TBL] [Abstract][Full Text] [Related]
8. Nuclear receptor drug discovery.
Chen T
Curr Opin Chem Biol; 2008 Aug; 12(4):418-26. PubMed ID: 18662801
[TBL] [Abstract][Full Text] [Related]
9. Development of silicon-containing bis-phenol derivatives as androgen receptor antagonists: selectivity switching by C/Si exchange.
Nakamura M; Makishima M; Hashimoto Y
Bioorg Med Chem; 2013 Apr; 21(7):1643-51. PubMed ID: 23462715
[TBL] [Abstract][Full Text] [Related]
10. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes.
Wang H; LeCluyse EL
Clin Pharmacokinet; 2003; 42(15):1331-57. PubMed ID: 14674787
[TBL] [Abstract][Full Text] [Related]
11. Targeting RORs nuclear receptors by novel synthetic steroidal inverse agonists for autoimmune disorders.
Dal Prà M; Carta D; Szabadkai G; Suman M; Frión-Herrera Y; Paccagnella N; Castellani G; De Martin S; Ferlin MG
Bioorg Med Chem; 2018 May; 26(8):1686-1704. PubMed ID: 29477813
[TBL] [Abstract][Full Text] [Related]
12. Antagonist- and inverse agonist-driven interactions of the vitamin D receptor and the constitutive androstane receptor with corepressor protein.
Lempiäinen H; Molnár F; Macias Gonzalez M; Peräkylä M; Carlberg C
Mol Endocrinol; 2005 Sep; 19(9):2258-72. PubMed ID: 15905360
[TBL] [Abstract][Full Text] [Related]
13. Detection of potential ligands for nuclear receptors in cellular extracts.
Zeng Z; Allan GF; Thaller C; Cooney AJ; Tsai SY; O'Malley BW; Tsai MJ
Endocrinology; 1994 Jul; 135(1):248-52. PubMed ID: 8013359
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of nuclear receptor-degradation inducers.
Itoh Y; Kitaguchi R; Ishikawa M; Naito M; Hashimoto Y
Bioorg Med Chem; 2011 Nov; 19(22):6768-78. PubMed ID: 22014751
[TBL] [Abstract][Full Text] [Related]
15. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?
Mulholland DJ; Dedhar S; Coetzee GA; Nelson CC
Endocr Rev; 2005 Dec; 26(7):898-915. PubMed ID: 16126938
[TBL] [Abstract][Full Text] [Related]
16. Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors.
Petit-Topin I; Fay M; Resche-Rigon M; Ulmann A; Gainer E; Rafestin-Oblin ME; Fagart J
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt B():427-35. PubMed ID: 25204619
[TBL] [Abstract][Full Text] [Related]
17. Differential modulation of androgen receptor transcriptional activity by the nuclear receptor co-repressor (N-CoR).
Berrevoets CA; Umar A; Trapman J; Brinkmann AO
Biochem J; 2004 May; 379(Pt 3):731-8. PubMed ID: 14744261
[TBL] [Abstract][Full Text] [Related]
18. Development of functional molecules for elucidation of the physiological roles of several nuclear receptors and their endogenous ligands.
Hirano T
Chem Pharm Bull (Tokyo); 2013; 61(2):111-20. PubMed ID: 23370193
[TBL] [Abstract][Full Text] [Related]
19. 4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor.
Wakabayashi K; Imai K; Miyachi H; Hashimoto Y; Tanatani A
Bioorg Med Chem; 2008 Jul; 16(14):6799-812. PubMed ID: 18571420
[TBL] [Abstract][Full Text] [Related]
20. [Development of novel nuclear receptor ligands based on receptor-folding inhibition hypothesis].
Tanatani A
Yakugaku Zasshi; 2007 Feb; 127(2):341-51. PubMed ID: 17268154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
